More Evidence Backs CBD For Kids' Rare Epilepsy

WebMD

TUESDAY, April 30, 2019 (HealthDay News) — There’s new data supporting the use of Epidiolex — the first cannabidiol (CBD) medicine approved by the U.S. Food and Drug Administration — to help curb a form of epilepsy.

The research found that the drug reduced seizures by nearly half in children with Dravet syndrome, a rare and severe form of the neurological disorder.

The FDA approved Epidiolex last fall for the treatment of Dravet syndrome and another rare but severe form of childhood epilepsy, Lennox-Gastaut syndrome. The new study was funded by GW Research Ltd., developer of Epidiolex.

Dravet syndrome typically begins in infancy and can lead to intellectual disability and frequent, prolonged seizures, noted a team of researchers led by Dr. Ian Miller, from Nicklaus Children’s Hospital in Miami.

“It’s exciting to be able to offer another alternative for children with this debilitating form of epilepsy and their families,” Miller said. He and his colleagues will present their findings next week at the American Academy of Neurology’s annual meeting, in Philadelphia.

“The children in this study had already tried an average of four epilepsy drugs with no success and at the time were taking an average of three additional drugs, so to have this measure of success with cannabidiol is a major victory,” Miller said in a meeting news release.

The study included 199 patients, average age 9, who were divided into three groups. One group received 20 milligrams per kilogram (mg/kg) dose per day of Epidiolex (in liquid form), while the second group received 10 mg/kg per day, and the third group received a placebo.

CBD products are derived from marijuana, but do not include THC, the active agent in pot that causes a “high.”

After 14 weeks of treatment, seizures with convulsions fell 46% in the high-dose group, 49% in the low-dose group, and 27% in the placebo group.

Total seizures fell 47% in the high-dose group, 56% in the low-dose group, and 30% in the placebo group.

Seizures were reduced by half or more in 49% of the high-dose group, 44% of the low-dose group, and 26% of the placebo group.

Original Article Source: https://www.webmd.com/epilepsy/news/20190430/more-evidence-backs-cbd-for-kids-rare-epilepsy?src=RSS_PUBLIC

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...

Norma Pence

Search This Blog